NIH Psilocybin Research Speaker Series (Registration)

Submitted by nusratyj on Tue, 04/13/2021 - 14:50


Please use the form below to select the seminar series you would like to attend.


OMB No.: 0925-0740
Expiration Date: 07/31/2022

Public reporting burden for this collection of information is estimated to average 3 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0740). Do not return the completed form to this address.



Select all upcoming seminars you would like to attend:

3:00-4:00 PM EST -  Psilocybin at the End of Life
Charles Grob, M.D. Professor of Psychiatry and Pediatrics, UCLA School of Medicine

4:00-5:00 PM EST -  Psilocybin: Neuropsychopharmacology and Implications for Therapeutics
Roland Griffiths, Ph.D. Professor of Psychiatry and Behavioral Sciences, JHU School of Medicine
11:00-12:00 PM EST  - What’s at Stake, Strategic Science Policy Considerations for Advancing Public Health through Dynamic Regulatory Frameworks
Sean Belouin, Pharm.D. CAPT, United States Public Health Service, Senior Science Policy Advisor, SAMHSA

12:00-12:45 PM EST - A Breast Cancer Patient’s Perspectives on the Uses of Psychedelics in Medicine
Erica Rex, MA. Journalist & Writer for Scientific American and The New York Times, National Magazine Award Winner.

12:45-1:30 PM EST - Psilocybin in Cancer Patients with Depression---The Experience at Aquilino Cancer Center
Manish Agrawal, M.D. Cancer center Director, Aquilino Cancer Center
1:00-1:30 pm EST  -  Self-blinding Citizen Science to Explore Psychedelic Microdosing
Balázs Szigeti, PhD. Center for Psychedelic Research, Imperial College London

1:30-2:30 pm EST - Psilocybin and Group Therapy: Implications for Safety and Efficacy
Brian Anderson, M.D, MSC. Assistant Professor, Psychiatry, UCSF School of Medicine
Alicia Danforth, Ph.D. Clinical Psychologist
2:00-2:45 PM EST - New Insights into the Mechanism of Action of Psilocybin

2:45-3:20 PM EST - Preclinical experimental systems to study antidepressant-like effects of psilocybin
Charles Nichols, PhD. Professor, Department of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center

3:20-4:00 PM EST - Harnessing psilocybin to fight depression: Insights and provocations from preclinical studies
Scott Thompson, Ph.D. Professor and Chair, Department of Physiology, UMD School of Medicine

4:00-4:30 PM EST - Synthesis, characterization, and preclinical pharmacology of psilocybin analogs and related tryptamines
Grant Glatfelter, Ph.D. Postdoctoral Fellow, Designer Drug Research Unit, IRP, NIDA, NIH
1:00-1:40 PM EST - Psilocybin-Assisted Psychotherapy for Advanced Cancer-related Psychiatric and Existential Distress
Stephen Ross, M.D. Associate Professor, Department of Psychiatry at NYU Grossman School of Medicine

1:40-2:15 pm - EST Psychedelic Medicine and Ethics
Paul S. Appelbaum, MD. Dollard Professor of Psychiatry, Medicine, & Law, Columbia University College of Physicians & Surgeons
Mason Marks, MD, JD. Assistant Professor of Law, Gonzaga University
William Smith, MD, PhD, Psychiatry Resident, Perelman School of Medicine, University of Pennsylvania

2:15-3:00 PM EST - Final Panel Discussion
TBD, FDA and NIH Staff

Individuals with disabilities who need Sign Language Interpreters and/or reasonable accommodation to participate in this event should contact Dr. Terry Moody,, 240-276-7785, or Dr. Dan Xi,, 240-276-6143, and/or the Federal Relay (1-800-877-8339) 2 days before the event.